The vaccine is not yet there but already 5.3 billion doses have been pre-purchased by rich countries representing 13% of the world population.
Will poor countries go after everyone else to access the Covid-19 vaccine? According to a report fromONG Oxfam, 51% of future doses have been pre-purchased by a group of rich countries representing 13% of the world population, report Time.
The report urgently underlines the difficulty that part of the world’s population will have in finding vaccines in the initial period. ”
For Oxfam, “Vital access to vaccines should not depend on where you live or how much money you have”.
Race to delivery
The US, UK, EU, Japan, Australia, Hong Kong, Switzerland and Israel have reserved 5.3 billion doses from five phased manufacturers III clinical trials, thus ensuring “In advance of the production and delivery of doses if the clinical trials in progress are conclusive”. In this race for supplies, the Americans would even be delivered in October, to distribute the vaccine within 24 hours of a possible health authorization.
Oxfam figures are based on five of the nine vaccines currently in phase III for which the pre-supply contracts have been made public, namely the European group AstraZeneca, the Russian Gamaleïa institute, the American biotechnology company Moderna, the American Pfizer and the Chinese laboratory Sinovac.
Even in the case “Extremely unlikely”, according to Oxfam, where all five vaccines would pass clinical trials, 61% of the world’s population will not have a vaccine until at least 2022.
The rest of the pre-purchases analyzed by theONG are divided between “India, where the giant manufacturer Serum Institute of India is located, Bangladesh, China, Brazil, Indonesia and Mexico”.
The Covax international pooling system supported byWHO, which would make the vaccine available to everyone, is “Boycotted by Washington and lack of funding”, recalls the Swiss daily.
Born in March 1998 from the merger of New Daily, of Geneva Journal and some Gazette of Lausanne, this center-right title, popular with executives, is presented as the benchmark daily in French-speaking Switzerland and